A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

Background: Currently, nanoliposomal irinotecan (nal-IRI) + 5-fluorouracil/folinic acid (5-FU/LV) is the only approved second-line treatment for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). However, also other chemotherapeutic regimens are used in this setting and due to the lack of clear real-world data on the efficacy of the different regimens, there is no consensus on the optimal treatment sequence for mPDAC patients. Objectives: To provide information on the safe and efficacious use of nal-IRI + 5-FU/LV in clinical practice in Belgium, which is needed for he... Mehr ...

Verfasser: Lise Verbruggen
Lisa Verheggen
Greetje Vanhoutte
Catherine Loly
Willem Lybaert
Ivan Borbath
Philippe Vergauwe
Koen Hendrickx
Celine Debeuckelaere
Amy de Haar-Holleman
Jean-Luc Van Laethem
Marc Peeters
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Verlag/Hrsg.: SAGE Publishing
Schlagwörter: Neoplasms. Tumors. Oncology. Including cancer and carcinogens / RC254-282
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26613628
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1177/17588359231181500